SCHEMBL6996772

SCHEMBL6996772

C/C=C/CC1CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19595018 1.00
SCHEMBL3935708 1.00
SCHEMBL3932444 0.88
SCHEMBL397148 0.88
SCHEMBL7909866 0.87 NOS2 (0.35)
SCHEMBL11896317 0.87 NOS2 (0.35)
SCHEMBL9457704 0.87 NOS2 (0.35)
SCHEMBL7911976 0.87 NOS2 (0.35)
SCHEMBL9017190 0.87 NOS2 (0.35)
SCHEMBL7910017 0.87 NOS2 (0.35)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1090005-B1 PYRAZOLO 1,5-a]TRIAZINE CORTICOTROPIN RELEASING FACTOR ANTAGONISTS BRISTOL MYERS SQUIBB PHARMA CO (US) 2003-08-20 EP claimed
US-6509338-B1 Psychiatric disorders and neurological diseases including affective disorder, anxiety, depression, headache, irritable bowel syndrome, post-traumatic stress disorder, supranuclear palsy, immune suppression, Alzheimer's disease, BRISTOL-MYERS SQUIBB COMPANY 2003-01-21 US claimed
EP-1090005-A1 PYRAZOLO 1,5-a]TRIAZINE CORTICOTROPIN RELEASING FACTOR ANTAGONISTS Du Pont Pharmaceuticals Company (US) 2001-04-11 EP claimed
WO-1999067247-A1 PYRAZOLO[1,5-a]TRIAZINE CORTICOTROPIN RELEASING FACTOR ANTAGONISTS DU PONT PHARMACEUTICALS COMPANY (US) 1999-12-29 WO claimed
CN-104812748-B Pyrazoline GPR40 conditioning agents 百时美施贵宝公司 2017-10-24 CN disclosed
EP-1090005-B1 PYRAZOLO 1,5-a]TRIAZINE CORTICOTROPIN RELEASING FACTOR ANTAGONISTS BRISTOL MYERS SQUIBB PHARMA CO (US) 2003-08-20 EP disclosed
US-6509338-B1 Psychiatric disorders and neurological diseases including affective disorder, anxiety, depression, headache, irritable bowel syndrome, post-traumatic stress disorder, supranuclear palsy, immune suppression, Alzheimer's disease, BRISTOL-MYERS SQUIBB COMPANY 2003-01-21 US disclosed
EP-1090005-A1 PYRAZOLO 1,5-a]TRIAZINE CORTICOTROPIN RELEASING FACTOR ANTAGONISTS Du Pont Pharmaceuticals Company (US) 2001-04-11 EP disclosed
WO-1999067247-A1 PYRAZOLO[1,5-a]TRIAZINE CORTICOTROPIN RELEASING FACTOR ANTAGONISTS DU PONT PHARMACEUTICALS COMPANY (US) 1999-12-29 WO disclosed